Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Palovarotene Ophthalmic Solution in Healthy Adults
NCT04762355Phase 1Completed
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of palovarotene in dry eye disease (DED) (3 arms), sponsored by Clementia Pharmaceuticals Inc. Primary endpoints: Treatment-Emergent Adverse Events up to 25 days, Best-Corrected Visual Acuity up to 25 days and 2 more. Started Aug 2018; status: completed.
02
Drugs
palovarotene
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04762355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762355.